The treatment of CRA/IFN and paclitaxel was designed to modulate Bcl-2 mediated drug resistance based on studies demonstrating that Bcl-2 over-expression is implicated as a cause of hormonal and chemotherapy resistance in prostate cancer, and prior studies demonstrating an effect of CRA/IFN on Bcl-2 regulation [3-6]. This evidence concerns the gene BCL2 and prostate carcinoma.